These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 32074225)
41. A malignant hyperthermia-like reaction in a six-month-old female with a 5q chromosomal deletion. Greenberg M; Faierman A; Fisher B; Harris B Can J Anaesth; 2005; 52(7):772-3. PubMed ID: 16103395 [No Abstract] [Full Text] [Related]
42. Malignant hyperthermia developing during esophageal resection in an 82-year-old man. Nakamura N; Ueda T; Ishikawa R; Tasaka Y; Fukuuchi K; Sato N J Anesth; 2008; 22(4):464-6. PubMed ID: 19011791 [TBL] [Abstract][Full Text] [Related]
43. Malignant hyperthermia in the absence of triggering agents. Setzer-Saade N Anesth Analg; 2010 Sep; 111(3):822; author reply 822-3. PubMed ID: 20733170 [No Abstract] [Full Text] [Related]
44. Successful management of malignant hyperthermia during orthognathic surgery: a case report. Laureano Filho JR; de Oliveira Neto PJ; Duarte N; Caetana A; Chagas Ada S J Oral Maxillofac Surg; 2008 Jul; 66(7):1485-8. PubMed ID: 18571035 [No Abstract] [Full Text] [Related]
45. Delayed onset of malignant hyperthermia in desflurane anesthesia. Hoenemann CW; Halene-Holtgraeve TB; Booke M; Hinder F; Daudel F; Reich A; Van Aken H Anesth Analg; 2003 Jan; 96(1):165-7, table of contents. PubMed ID: 12505945 [TBL] [Abstract][Full Text] [Related]
46. Delayed onset of malignant hyperthermia in the intensive care unit: a rare but life-threatening disorder. Twine N Crit Care Nurs Q; 2013; 36(2):213-7. PubMed ID: 23470706 [TBL] [Abstract][Full Text] [Related]
47. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Riazi S; Larach MG; Hu C; Wijeysundera D; Massey C; Kraeva N Anesth Analg; 2014 Feb; 118(2):381-387. PubMed ID: 23842196 [TBL] [Abstract][Full Text] [Related]
48. A fatal case of malignant hyperthermia complicated by generalized compartment syndrome and rhabdomyolysis. Green G Acta Anaesthesiol Scand; 2003 May; 47(5):619-21. PubMed ID: 12699524 [TBL] [Abstract][Full Text] [Related]
49. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Brandom BW; Larach MG; Chen MS; Young MC Anesth Analg; 2011 May; 112(5):1115-23. PubMed ID: 21372281 [TBL] [Abstract][Full Text] [Related]
50. [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil]. Almeida da Silva HC; Ferreira G; Rodrigues G; Santos JMD; Andrade PV; Hortense A; Vaz Perez M; Amaral JLGD Braz J Anesthesiol; 2019; 69(2):152-159. PubMed ID: 30935497 [TBL] [Abstract][Full Text] [Related]
51. Delayed onset of sevoflurane-induced juvenile malignant hyperthermia after second exposure. Chen PL; Day YJ; Su BC; Lee PC; Chen CY Acta Anaesthesiol Taiwan; 2007 Sep; 45(3):189-93. PubMed ID: 17972624 [TBL] [Abstract][Full Text] [Related]
52. Minor increase of endtidal CO2 during sevoflurane-induced malignant hyperthermia. Bonciu M; de la Chapelle A; Delpech H; Depret T; Krivosic-Horber R; Aimé MR Paediatr Anaesth; 2007 Feb; 17(2):180-2. PubMed ID: 17238892 [TBL] [Abstract][Full Text] [Related]